Co-administration of dehydroepiandrosterone (DHEA) congeners and other active agents for treating cancer
OwnerDinesh Patel, David Vollmer +2inventors
InventorsDinesh Patel, David Vollmer, Claire Daugherty, John Gebhard
Life of this patent
Estimating the term…
Abstract
The present invention is related to therapeutic uses of dehydroepiandrosterone (DHEA) congeners. More specifically, the present invention relates to the co-administration of a dehydroepiandrosterone (DHEA) congener in combination with at least one other pharmaceutically active agent to treat or prevent cancer.
Claims22
A method of treating a subject with cancer or inflammation associated with cancer, comprising co-administering to the subject a therapeutically effective amount of a DHEA congener and a second anti-inflammatory agent.
A method as in claim 7, wherein the COX-2 inhibitor is selected from the group consisting of celecoxib, rofecoxib, valdecoxib, parecoxib, lumiracoxib, and combinations thereof.
A method as in claim 52, wherein the COX-2 inhibitor is celecoxib.
A method of inhibiting the growth of pancreatic cancer in a subject, comprising co-administering a therapeutically effective amount of a DHEA congener and a COX-2 inhibitor to the subject.
Dependencies are inferred from the claim text.